期刊论文详细信息
Cancers
Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma
Michael Ohlmeyer1  Elizabeth Mroczek-Musulman2  Karina J. Yoon3  Jamie M. Aye4  Sara C. Hutchins4  Janet R. Julson5  Laura V. Bownes5  Elizabeth A. Beierle5  Michael H. Erwin5  Andee M. Beierle5  Colin H. Quinn5  Raoud Marayati5  Jerry E. Stewart5 
[1] Atux Iskay LLC, Plainsboro, NJ 08536, USA;Department of Pathology, Children’s of Alabama, Birmingham, AL 35233, USA;Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35233, USA;Division of Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA;Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA;
关键词: protein phosphatase 2A;    neuroblastoma;    patient-derived xenograft;    CIP2A;    MYCN;   
DOI  :  10.3390/cancers14081952
来源: DOAJ
【 摘 要 】

Background: Protein phosphatase 2A (PP2A) functions as an inhibitor of cancer cell proliferation, and its tumor suppressor function is attenuated in many cancers. Previous studies utilized FTY720, an immunomodulating compound known to activate PP2A, and demonstrated a decrease in the malignant phenotype in neuroblastoma. We wished to investigate the effects of two novel PP2A activators, ATUX-792 (792) and DBK-1154 (1154). Methods: Long-term passage neuroblastoma cell lines and human neuroblastoma patient-derived xenograft (PDX) cells were used. Cells were treated with 792 or 1154, and viability, proliferation, and motility were examined. The effect on tumor growth was investigated using a murine flank tumor model. Results: Treatment with 792 or 1154 resulted in PP2A activation, decreased cell survival, proliferation, and motility in neuroblastoma cells. Immunoblotting revealed a decrease in MYCN protein expression with increasing concentrations of 792 and 1154. Treatment with 792 led to tumor necrosis and decreased tumor growth in vivo. Conclusions: PP2A activation with 792 or 1154 decreased survival, proliferation, and motility of neuroblastoma in vitro and tumor growth in vivo. Both compounds resulted in decreased expression of the oncogenic protein MYCN. These findings indicate a potential therapeutic role for these novel PP2A activators in neuroblastoma.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次